Gregory Stone, PhD

Director of Microbiology
Pfizer, Inc.

Poster(s):

• (2127) In vitro Activities of Ceftaroline and Comparator Agents against Bacterial Pathogens Frequently Causing Community-Acquired Respiratory Tract Infections in Patients from a Global Population: ATLAS Surveillance Program 2018-2021
  Saturday, October 14, 2023

  12:15 PM – 1:30 PM US ET

• (2128) In Vitro Activity of Ceftibuten-Avibactam and Comparator Agents Against Resistant Enterobacterales from UTIs Collected Globally as Part of the ATLAS Surveillance Program, 2022
  Saturday, October 14, 2023

  12:15 PM – 1:30 PM US ET

• (2151) In Vitro Activity of Ceftazidime-Avibactam and Comparator Agents Against Pseudomonas aeruginosa Collected from Patients with Presumed Hospital- and Community-Acquired Respiratory Tract Infections: ATLAS Global Surveillance Program, 2017-2021
  Saturday, October 14, 2023

  12:15 PM – 1:30 PM US ET

• (2826) Epidemiology of Extended Spectrum Beta-lactamase (ESBL)-producing Enterobacterales and Antimicrobial Resistance in Urinary Tract Infection (UTI) and Acute Pyelonephritis (AP)
  Saturday, October 14, 2023

  12:15 PM – 1:30 PM US ET